Nouri A M, Lowdell M, Entazami Z, Tezabwala B U, Goode A, Oliver R T
Department of Medical Oncology, The Royal London Hospital, UK.
Urol Int. 1996;56(1):1-5. doi: 10.1159/000282798.
The effects of the route of administration of interleukin 2 (IL-2) on the immunological parameters of patients with various malignancies were investigated. The percent mean values for IL-2 receptor (Tac) positive cells among mononuclear cells in patients receiving IL-2 subcutaneously (5 cases) or intravenously (6 cases) were 7 and 7%, respectively. The corresponding values of post-IL-2 treatment peak were 18 and 16%. Similarly, the values for class II antigen expressing cells were 12 and 16% and 25 and 26%. In no case the difference between the values for the subcutaneous or the intravenous route reached significance. Using the 51Cr release assay, the mean percent killing activity of IL-2-activated mononuclear cells against Daudi tumour target cells for the subcutaneously and the intravenously treated groups were 27 and 14% and the corresponding values for the post-IL-2 treatment peak were 59% (p > 0.05) and 69% (p > 0.05), respectively. The similar values using K562 tumour as target were 17 and 8%, and the corresponding values for post-treatment peak were 55% (p > 0.05) and 23% (p > 0.05). In all cases the cytotoxic values for the post-IL-2 treatment were significantly greater than the pre-IL-2 values. The mean (+/- SD) values for serum beta2-m levels for 6 subcutaneously and 5 intravenously IL-2-treated patients were 6.5 +/- 4.6 and 5.7 +/- 3.4 mg/l (p > 0.05). The corresponding values for post-IL-2 (15 days) were 9.1 +/- 3.4 and 9.9 +/- 5.1 mg/1, respectively. These results demonstrate that there is no significant difference in the immunological parameters in cancer patients receiving IL-2 via subcutaneous or intravenous routes and provide further support for the current trend for clinical trials to concentrate on outpatients subcutaneous administration.
研究了白细胞介素2（IL-2）给药途径对各种恶性肿瘤患者免疫参数的影响。皮下注射（5例）或静脉注射（6例）IL-2的患者单核细胞中IL-2受体（Tac）阳性细胞的平均百分比分别为7%和7%。IL-2治疗后峰值的相应值分别为18%和16%。同样，II类抗原表达细胞的值分别为12%和16%以及25%和26%。皮下或静脉途径的值之间在任何情况下均无显著差异。使用51Cr释放试验，皮下和静脉治疗组的IL-2激活单核细胞对Daudi肿瘤靶细胞的平均杀伤活性百分比分别为27%和14%，IL-2治疗后峰值的相应值分别为59%（p>0.05）和69%（p>0.05）。以K562肿瘤为靶标的类似值分别为17%和8%，治疗后峰值的相应值分别为55%（p>0.05）和23%（p>0.05）。在所有情况下，IL-2治疗后的细胞毒性值均显著高于IL-2治疗前的值。6例皮下注射和5例静脉注射IL-2治疗患者的血清β2-m水平平均（±标准差）值分别为6.5±4.6和5.7±3.4mg/l（p>0.05）。IL-2治疗后（15天）的相应值分别为9.1±3.4和9.9±5.1mg/1。这些结果表明，皮下或静脉途径接受IL-2的癌症患者免疫参数无显著差异，并为目前临床试验集中于门诊皮下给药的趋势提供了进一步支持。
